ClinicalTrials.gg
CompletedNCT03254914Updated Dec 27, 2024

Fimasartan Optimal Reduction Targeting Elevated Blood Pressure: the FORTE Study

An observational study in Hypertension, sponsored by Boryung Pharmaceutical Co., Ltd. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2024-12-27.

Sponsored by Boryung Pharmaceutical Co., Ltd · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
3,554
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 40 studies in Hypertension by Boryung Pharmaceutical Co., Ltd — 1 open to participants now, 1 under way, none of them phase 3. Hypertension · Boryung Pharmaceutical Co., Ltd.

Started
2017
with 2 others
Observational
8 of 40
1 open now
Registered
29th of 40
by date

Among the 40 studies in Hypertension by Boryung Pharmaceutical Co., Ltd, this one is one of 3 that started in 2017, is one of 8 observational ones, and was the 29th registered.

Hypertension

6,125 studies on the registry are indexed under Hypertension; 910 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 40 studies in Hypertension by Boryung Pharmaceutical Co., Ltd is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 557 Hypertension studies recruiting now, 264 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 138 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Hypertension by Boryung Pharmaceutical Co., Ltd, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect of home blood pressure monitoring on controlling blood pressure and correlation between home blood pressure and clinic blood pressure in hypertensive patients receiving two or more concomitant antihypertensive agents including fimasartan

Read the detailed description

A multi-center, cluster-randomized, prospective, observational study

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Home Blood Pressure
  • Fimasartan
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Hypertensive patients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who voluntarily signed for participating in this clinical study
  • Male and female over the age of 19
  • Hypertensive patients receiving two or more concomitant anti-hypertensive agents including fimasartan

Exclusion criteria

Exclusion Criteria:

  • Renal dialysis patients.
  • Diabetic nephropathy patients taking angiotensin-converting enzyme inhibitor.
  • Severe renal disorder
  • Subjects with hereditary disorders of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
  • Medical history with to Fimasartan
  • Pregnant women or lactating female.
  • Participate in another clinical trial.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
3,554 participants (actual)
Target follow-up
12 Weeks
Patient registry
Yes

Groups and cohorts

  • Control Site

    Measure Clinic Blood Pressure

  • Test Site

    Measure Clinic Blood Pressure and Home Blood Pressure

    Procedure: Home Blood Pressure

Interventions

  • ProcedureHome Blood Pressure

    Measure Home Blood Pressure

06

What researchers measure

Primary outcomes

  1. Rate of reaching target blood pressure

    Rate of reaching target blood pressure after treatment for 12 weeks

    Time frame: 12 weeks after treatment

07

Study locations

1 site
  • Seoul national university hospital
    Seoul, Korea, Republic of
08

References and documents

Publications

  • Choi JY, Kim KI, Kim CH. Effect of home blood pressure monitoring for blood pressure control in hypertensive patients taking multiple antihypertensive medications including fimasartan (the FORTE study). Clin Hypertens. 2020 Dec 15;26(1):24. doi: 10.1186/s40885-020-00154-y. PubMed 33317628 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Oct 2018, 14 months.

Of 81 industry-sponsored observational studies under Hypertension, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 45. This study's 14 months is below that.

Counting every sponsor, half of 429 studies reached it within 38 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2017
First posted
Aug 21, 2017
StartActual
Aug 9, 2017
Primary completionActual
Oct 31, 2018
CompletionActual
Feb 28, 2019
Last update
Dec 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03254914
Responsible party
Sponsor
First posted
Aug 21, 2017
Start date
Aug 9, 2017
Primary completion
Oct 31, 2018
Completion
Feb 28, 2019
Last update
Dec 27, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion